Amyotrophic Lateral Sclerosis: Current and Future Treatment Strategies
The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal, enigmatic disorder characterised by relentless progression of muscle wasting and weakness until death ensues due to respiratory muscle failure. Intellectual functions are usually spared. ALS, known also as motor neuron disease (MND) in the UK, maladie de Charcot in France and Lou Gehrig's disease in the US, is usually sporadic, but between 5 and 10% of all cases are hereditary, usually inherited as autosomal dominant. Previously thought to be untreatable, as well as incurable, just in the last 3 years ALS has been the greatest clinical application of recent exciting break-throughs in preclinical neurobiology research. Although definitive information regarding the cause(s) and pathogenesis of ALS still escapes us, meaningful demonstration of intercession in the downhill course with specific therapy has been suggested, giving reason to be hopeful, if cautiously and critically optimistic. This review focuses on the recent work from the fields of growth/trophic factors, glutamate/neurotoxicity, neuroprotection and proteases and inhibitors, as well as the approaches to measuring specific effects in patients with the illness. It ends with a eye to the horizon, and the future, and where ALS treatment strategies may be heading after the millennium.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase Mutation
Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., Caliendo, J., Hentati, A., Kwon, Y. W., Deng, H.-X., et al. (1994) · Science · doi:10.1126/science.8209258 · Cited by 4,143
Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis
Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, M., Gareau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A., et al. (1995) · Nature · doi:10.1038/376037a0 · Cited by 3,979
The Nerve Growth Factor 35 Years Later
Levi-Montalcini, R. (1987) · Science · doi:10.1126/science.3306916 · Cited by 3,125
Cell death during development of the nervous system
Oppenheim, R. W. (1991) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.14.030191.002321 · Cited by 3,084
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376
A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis
Bensimon, G., Lacomblez, L., & Meininger, V. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300901 · Cited by 2,233
Genetic control of programmed cell death in the nematode C. elegans
Ellis, H. (1986) · Cell · doi:10.1016/0092-8674(86)90004-8 · Cited by 1,828
GDNF: a Potent Survival Factor for Motoneurons Present in Peripheral Nerve and Muscle
Henderson, C. E., Phillips, H. S., Pollock, R. A., Davies, A. M., Lemeulle, C., Armanini, M., Simmons, L., Moffet, B., Vandlen, R. A., Koliatsos, V. E., et al. (1994) · Science · doi:10.1126/science.7973664 · Cited by 1,272
Cited by
Neuropharmacology of AMPA and kainate receptors
Bleakman, D., & Lodge, D. (1998) · Neuropharmacology · doi:10.1016/s0028-3908(98)00139-7 · Cited by 363
Fehlings, M. G., & Skaf, G. (1998) · Spine · doi:10.1097/00007632-199812150-00012 · Cited by 260
Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer
Speyer, C. L., Smith, J. S., Banda, M., DeVries, J. A., Mekani, T., & Gorski, D. H. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1624-x · Cited by 122
Quantification of upper motor neuron loss in amyotrophic lateral sclerosis
Rösler, K. M., Truffert, A., Hess, C. W., & Magistris, M. R. (2000) · Clinical Neurophysiology · doi:10.1016/s1388-2457(00)00481-8 · Cited by 93
Thatte, U. M., & Dahanukar, S. A. (1997) · Drugs · doi:10.2165/00003495-199754040-00002 · Cited by 95
Metadata
- Authors
- Festoff, B. W.
- Affiliations
- University of Kansas (US)
- Corresponding author
- Festoff, Barry W.
- ORCID
- Festoff, Barry W.
- Venue
- Drugs
- Published
- 1996-01
- Volume
- 51
- Issue
- 1
- Pages
- 28-44
- ISSN
- 0012-6667 (ISSN-L)
- OpenAlex
- W2121497477
- Cited by
- 35
- References
- 110
- Citations by year
- 2016: 1 · 2014: 3 · 2013: 2 · 2012: 1
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- amyotrophic lateral sclerosis, motor neuron disease, sporadic ALS, ALS pathogenesis, ALS treatment, neuroprotection, growth factors, trophic factors, glutamate excitotoxicity, proteolytic enzymes, protease inhibitors, muscle atrophy, respiratory muscle failure, biomarkers
- MeSH terms
- Amyotrophic Lateral Sclerosis, Clinical Trials as Topic, Humans, Insulin-Like Growth Factor I, Nerve Tissue Proteins, Thiazoles, Apoptosis, Riluzole, Ciliary Neurotrophic Factor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Amyotrophic Lateral Sclerosis: Current and Future Treatment Strategies. https://app.cochat.ai/papers/10.2165/00003495-199651010-00004
- The paper
- Festoff, B. W. (1996). Amyotrophic Lateral Sclerosis: Current and Future Treatment Strategies. Drugs. https://doi.org/10.2165/00003495-199651010-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.